Method for detection of effects of neohesperidin for resisting depression and promoting gastrointestinal motility

Abstract

The invention discloses a method for detection of effects of neohesperidin for resisting depression and promoting gastrointestinal motility. The method comprises the following steps of building a rat chronic unpredictable stress-combined social isolation model, carrying out forced swimming and an open-field test, carrying out gastric emptying and intestinal metastasis tests, and carrying out a brain-gut peptide test. The neohesperidin is a safe, efficient and stable drug for resisting depression and promoting gastrointestinal motility, can be prepared by the simple processes, has brain and intestine double-target point adjustment functions, has effects of resisting depression and promoting gastrointestinal motility, and has brain and intestine synchronous-adjustment effects on functional dyspepsia in a depression state. A preparation method of the neohesperidin has mature processes and a low cost, realizes safe effects, is suitable for industrial production and can be popularized easily.

Description

technical field [0001] The invention belongs to the field of biopharmaceuticals, and in particular relates to a method for detecting the effect of neohesperidin for antidepressant and promoting gastrointestinal motility. Background technique [0002] Depression and functional dyspepsia are common diseases at present, and they are closely related. Most patients with depression have symptoms of functional dyspepsia. Antidepressant strategies have become one of the effective treatments for functional dyspepsia and other psychosomatic diseases. Currently, there is no drug that can specifically treat gastrointestinal dysfunction based on depression. [0003] The existing first-line antidepressant drugs such as Prozac, etc., further inhibit gastrointestinal function while antidepressant, causing many toxic and side effects. Existing drugs for promoting gastrointestinal motility (mosapride, etc.) can only simply promote gastrointestinal motility without any improvement on the depr...

AI Technical Summary

Problems solved by technology

[0004] In the existing literature reports, there is no specific drug for functional dyspepsia based on depressive state

In the current complex disease of depression and functional dyspepsia, it is difficult to achieve satisfactory curative effect by simply antidepressant or purely promoting gastrointestinal motility

[0005] At present, antidepressants only target the brain target, ignoring the impact on the gastrointestinal tract, leading to further aggravation of gastrointestinal dysfunction

[0006] Secondly, the existing gastrointestinal motility drugs only target gastrointestinal targets, ignoring the effect of the brain on the regulation of gastrointestinal function, resulting in large fluctuations in curative effect

[0007] Third, there are no drugs that have both antidepressant and gastrointestinal motility effects

Images